Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN V SHERMAN

Allopathic & Osteopathic Physicians Obstetrics & Gynecology

NPI
1871574590
CMS profile
266884
Location
GEORGETOWN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$524.76

27 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $524.76 27

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $357.80 24
CooperSurgical, Inc. $123.57 1
Organon LLC $22.70 1
Axonics, Inc. $20.69 1

Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN V SHERMAN

NPI 1871574590 · CMS profile ID 266884

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology

GEORGETOWN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1871574590?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN V SHERMAN, NPI 1871574590, CMS profile ID 266884. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871574590?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JOHN V SHERMAN, NPI 1871574590, CMS profile ID 266884. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871574590?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JOHN V SHERMAN, NPI 1871574590, CMS profile ID 266884, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1871574590?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

27 matching records · $524.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 27 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–27 of 27.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $19.4911/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027999 CMS
CooperSurgical, Inc. $123.5711/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826651201 CMS
AbbVie Inc. $15.9410/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027997 CMS
AbbVie Inc. $5.9710/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027993 CMS
AbbVie Inc. $2.0210/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027995 CMS
AbbVie Inc. $22.0110/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027991 CMS
AbbVie Inc. $7.0209/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027989 CMS
Organon LLC $22.7009/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837292759 CMS
AbbVie Inc. $18.9009/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027987 CMS
AbbVie Inc. $14.3708/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027985 CMS
AbbVie Inc. $2.5007/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027983 CMS
AbbVie Inc. $4.0507/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027981 CMS
AbbVie Inc. $12.9407/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027979 CMS
AbbVie Inc. $1.1106/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027977 CMS
AbbVie Inc. $9.3406/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027975 CMS
AbbVie Inc. $14.0406/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027973 CMS
AbbVie Inc. $9.1806/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027971 CMS
AbbVie Inc. $6.8606/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027969 CMS
AbbVie Inc. $16.7505/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027967 CMS
AbbVie Inc. $9.8404/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027965 CMS
AbbVie Inc. $10.6604/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027961 CMS
AbbVie Inc. $96.1904/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027963 CMS
AbbVie Inc. $13.2504/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027959 CMS
AbbVie Inc. $17.8003/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027957 CMS
AbbVie Inc. $10.9102/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027955 CMS
Axonics, Inc. $20.6901/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840595659 CMS
AbbVie Inc. $16.6601/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796027953 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,489.27 14
PY2020 $83.76 5
PY2021 $524.76 27
PY2022 $336.63 22
PY2023 $47.62 2
PY2024 $35.56 2
PY2025 $212.53 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $2,200.00 1
PY2023 Principal investigator $60,786.66 18
PY2022 Principal investigator $277,370.20 109
PY2021 Principal investigator $310,510.11 86
PY2020 Principal investigator $196,011.16 44
PY2019 Principal investigator $60,183.92 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

109 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $3,378.81 12/30/2022 Non-covered Recipient Entity
FMC Science LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949777195
Principal investigator 1 GlaxoSmithKline, LLC. $720.72 12/07/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000253
Principal investigator 1 GlaxoSmithKline, LLC. $180.18 12/07/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000359
Principal investigator 1 PFIZER INC. $3,401.44 12/06/2022 Non-covered Recipient Entity
FMC Science LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949777157
Principal investigator 1 GlaxoSmithKline, LLC. $862.29 11/23/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000159
Principal investigator 1 GlaxoSmithKline, LLC. $180.18 11/23/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000401
Principal investigator 1 GlaxoSmithKline, LLC. $990.99 11/23/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000407
Principal investigator 1 GlaxoSmithKline, LLC. $1,891.89 11/23/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000453
Principal investigator 1 GlaxoSmithKline, LLC. $862.29 11/23/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000465
Principal investigator 1 GlaxoSmithKline, LLC. $283.14 11/09/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000283
Principal investigator 1 PFIZER INC. $408.87 11/05/2022 Non-covered Recipient Entity
FMC Science LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949780645
Principal investigator 1 GlaxoSmithKline, LLC. $360.36 10/25/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000065
Principal investigator 1 GlaxoSmithKline, LLC. $862.29 10/25/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000105
Principal investigator 1 GlaxoSmithKline, LLC. $463.32 10/25/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000119
Principal investigator 1 GlaxoSmithKline, LLC. $180.18 10/25/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000173
Principal investigator 1 GlaxoSmithKline, LLC. $180.18 10/25/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000271
Principal investigator 1 GlaxoSmithKline, LLC. $862.29 10/25/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000471
Principal investigator 1 PFIZER INC. $3,279.95 10/25/2022 Non-covered Recipient Entity
FMC Science LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949788421
Principal investigator 1 GlaxoSmithKline, LLC. $360.36 10/12/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000371
Principal investigator 1 GlaxoSmithKline, LLC. $990.99 10/12/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000377
Principal investigator 1 GlaxoSmithKline, LLC. $2,084.94 10/03/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000429
Principal investigator 1 GlaxoSmithKline, LLC. $862.29 09/27/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000423
Principal investigator 1 PFIZER INC. $8,794.87 09/22/2022 Non-covered Recipient Entity
FMC Science LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949788423
Principal investigator 1 GlaxoSmithKline, LLC. $862.29 09/14/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000231
Principal investigator 1 GlaxoSmithKline, LLC. $180.18 09/14/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000277
Principal investigator 1 PFIZER INC. $5,059.47 09/02/2022 Non-covered Recipient Entity
FMC Science LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949788447
Principal investigator 1 GlaxoSmithKline, LLC. $4,620.33 09/01/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000091
Principal investigator 1 GlaxoSmithKline, LLC. $540.54 09/01/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000295
Principal investigator 1 GlaxoSmithKline, LLC. $6,357.78 09/01/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000389
Principal investigator 1 GlaxoSmithKline, LLC. $540.54 09/01/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000513
Principal investigator 1 GlaxoSmithKline, LLC. $4,421.34 09/01/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000563
Principal investigator 1 ABBVIE INC. $1,500.00 08/25/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890366677
Principal investigator 1 GlaxoSmithKline, LLC. $1,589.94 08/17/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000219
Principal investigator 1 GlaxoSmithKline, LLC. $1,724.58 08/17/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000225
Principal investigator 1 ABBVIE INC. $1,401.30 08/10/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890366679
Principal investigator 1 PFIZER INC. $6,418.29 08/05/2022 Non-covered Recipient Entity
FMC Science LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949803487
Principal investigator 1 GlaxoSmithKline, LLC. $264.33 08/01/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000365
Principal investigator 1 GlaxoSmithKline, LLC. $1,171.17 08/01/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000519
Principal investigator 1 GlaxoSmithKline, LLC. $2,240.37 08/01/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000545
Principal investigator 1 GlaxoSmithKline, LLC. $2,750.00 07/20/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000071
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 07/20/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000147
Principal investigator 1 GlaxoSmithKline, LLC. $2,250.00 07/20/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000153
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 07/20/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000213
Principal investigator 1 GlaxoSmithKline, LLC. $2,316.60 07/20/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000483
Principal investigator 1 GlaxoSmithKline, LLC. $3,750.00 07/20/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000507
Principal investigator 1 GlaxoSmithKline, LLC. $2,625.48 07/20/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000551
Principal investigator 1 ABBVIE INC. $5,000.00 07/13/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890365011
Principal investigator 1 PFIZER INC. $777.46 07/09/2022 Non-covered Recipient Entity
FMC Science LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949806709
Principal investigator 1 PFIZER INC. $1,288.66 06/24/2022 Non-covered Recipient Entity
FMC Science LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949812807
Principal investigator 1 GlaxoSmithKline, LLC. $1,435.50 05/25/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000165
Principal investigator 1 GlaxoSmithKline, LLC. $450.00 05/25/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000209
Principal investigator 1 GlaxoSmithKline, LLC. $1,332.54 05/25/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000383
Principal investigator 1 GlaxoSmithKline, LLC. $444.51 05/25/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000435
Principal investigator 1 ABBVIE INC. $2,500.00 05/24/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890363397
Principal investigator 1 ABBVIE INC. $972.50 05/24/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890363415
Principal investigator 1 PFIZER INC. $30,663.05 05/21/2022 Non-covered Recipient Entity
FMC Science LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949754965
Principal investigator 1 GlaxoSmithKline, LLC. $1,145.43 05/11/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000495
Principal investigator 1 GlaxoSmithKline, LLC. $1,402.83 05/11/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000531
Principal investigator 1 ABBVIE INC. $26.19 05/04/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 890363417
Principal investigator 1 GlaxoSmithKline, LLC. $283.14 04/25/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000203
Principal investigator 1 PFIZER INC. $2,730.40 04/22/2022 Non-covered Recipient Entity
FMC Science LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949822017
Principal investigator 1 GlaxoSmithKline, LLC. $1,126.62 04/21/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000259
Principal investigator 1 GlaxoSmithKline, LLC. $900.90 04/21/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000327
Principal investigator 1 GlaxoSmithKline, LLC. $360.36 04/21/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000441
Principal investigator 1 PFIZER INC. $8,496.74 04/08/2022 Non-covered Recipient Entity
FMC Science LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949821147
Principal investigator 1 GlaxoSmithKline, LLC. $720.72 04/06/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000045
Principal investigator 1 GlaxoSmithKline, LLC. $180.18 04/06/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000079
Principal investigator 1 GlaxoSmithKline, LLC. $1,261.26 04/06/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000099
Principal investigator 1 GlaxoSmithKline, LLC. $180.18 04/06/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000185
Principal investigator 1 GlaxoSmithKline, LLC. $180.18 04/06/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000345
Principal investigator 1 GlaxoSmithKline, LLC. $1,222.65 04/06/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000447
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 04/06/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000459
Principal investigator 1 GlaxoSmithKline, LLC. $5,077.71 04/06/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000477
Principal investigator 1 GlaxoSmithKline, LLC. $804.87 04/06/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000489
Principal investigator 1 GlaxoSmithKline, LLC. $720.72 03/23/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000243
Principal investigator 1 GlaxoSmithKline, LLC. $8,030.88 03/23/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000395
Principal investigator 1 GlaxoSmithKline, LLC. $3,140.28 03/23/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000501
Principal investigator 1 GlaxoSmithKline, LLC. $1,042.47 03/23/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000525
Principal investigator 1 GlaxoSmithKline, LLC. $5,020.29 03/16/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000191
Principal investigator 1 GlaxoSmithKline, LLC. $12,252.24 03/16/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000307
Principal investigator 1 GlaxoSmithKline, LLC. $1,467.18 03/16/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000557
Principal investigator 1 GlaxoSmithKline, LLC. $6,576.57 03/09/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000085
Principal investigator 1 GlaxoSmithKline, LLC. $283.14 03/09/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000179
Principal investigator 1 GlaxoSmithKline, LLC. $1,287.00 03/09/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000265
Principal investigator 1 GlaxoSmithKline, LLC. $3,726.36 03/09/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000315
Principal investigator 1 PFIZER INC. $16,615.43 03/04/2022 Non-covered Recipient Entity
FMC Science LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949821145
Principal investigator 1 GlaxoSmithKline, LLC. $3,032.37 02/22/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000053
Principal investigator 1 GlaxoSmithKline, LLC. $2,297.79 02/22/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000197
Principal investigator 1 GlaxoSmithKline, LLC. $733.59 02/22/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000321
Principal investigator 1 GlaxoSmithKline, LLC. $862.29 02/22/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000333
Principal investigator 1 GlaxoSmithKline, LLC. $2,586.87 02/22/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000339
Principal investigator 1 GlaxoSmithKline, LLC. $1,981.98 02/22/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000539
Principal investigator 1 GlaxoSmithKline, LLC. $2,683.89 02/09/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000125
Principal investigator 1 GlaxoSmithKline, LLC. $1,126.62 02/09/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000301
Principal investigator 1 GlaxoSmithKline, LLC. $3,836.25 02/09/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000413
Principal investigator 1 GlaxoSmithKline, LLC. $1,435.50 02/09/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000571
Principal investigator 1 ABBVIE INC. $320.00 02/04/2022 Non-covered Recipient Entity
FMCSCIENCE LLC
A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 889776011
Principal investigator 1 PFIZER INC. $10,720.25 01/25/2022 Non-covered Recipient Entity
FMC Science LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949829543
Principal investigator 1 GlaxoSmithKline, LLC. $1,866.15 01/24/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000059
Principal investigator 1 GlaxoSmithKline, LLC. $1,016.73 01/24/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000113
Principal investigator 1 GlaxoSmithKline, LLC. $1,860.21 01/24/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000133
Principal investigator 1 GlaxoSmithKline, LLC. $862.29 01/24/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000139
Principal investigator 1 GlaxoSmithKline, LLC. $547.47 01/24/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000237
Principal investigator 1 GlaxoSmithKline, LLC. $2,998.71 01/24/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000249
Principal investigator 1 GlaxoSmithKline, LLC. $2,658.15 01/24/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000291
Principal investigator 1 GlaxoSmithKline, LLC. $4,408.47 01/24/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000351
Principal investigator 1 GlaxoSmithKline, LLC. $1,834.47 01/24/2022 Non-covered Recipient Entity
FMC SCIENCE LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 944000419
Principal investigator 1 PFIZER INC. $4,977.00 01/11/2022 Non-covered Recipient Entity
FMCScience LLC
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 949829545
Principal investigator 1 PFIZER INC. $4,018.66 01/11/2022 Non-covered Recipient Entity
FMC Science LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 949829619

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 1
PY2024 Value of interest $1.00 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $1.00 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $1.00 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $1.00 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $1.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

5 records · PY2020–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 Unified Women's Healthcare, LP $0.00 $1.00 Physician holds an indirect ownership interest (Interest) in the GPO through his/her in equity interest in Unified Physician Management Holdings, LP (UPM Holdings). UPM Holdings and Unified Women's Healthcare, LP, the operator of the GPO, share a common general partner, Unified Physician Management, GP, LLC. The Interest is not freely transferable, remains subject to repurchase by UPM Holdings and physicians do not receive distributions of any kind related to the GPO. Physician Covered Recipient No dispute reported 06/30/2026 1069832591
PY2023 Unified Women's Healthcare, LP $0.00 $1.00 Physician holds an indirect ownership interest (Interest) in the GPO through his/her in equity interest in Unified Physician Management Holdings, LP (UPM Holdings). UPM Holdings and Unified Women's Healthcare, LP, the operator of the GPO, share a common general partner, Unified Physician Management, GP, LLC. The Interest is not freely transferable, remains subject to repurchase by UPM Holdings and physicians do not receive distributions of any kind related to the GPO. Physician Covered Recipient No dispute reported 06/30/2026 969611557
PY2022 Unified Women's Healthcare, LP $0.00 $1.00 Physician holds an indirect ownership interest (Interest) in the GPO through his/her in equity interest in Unified Physician Management Holdings LP (UPM Holdings). UPM Holdings and Unified Women's Healthcare LP the operator of the GPO share a common general partner Unified Physician Management GP LLC. The Interest is not freely transferable remains subject to a risk of forfeiture as of the date of this filing and repurchase by UPM Holdings. Physician Covered Recipient No dispute reported 06/30/2026 862656375
PY2021 Unified Women's Healthcare, LP $0.00 $1.00 Physician holds an indirect ownership interest (Interest) in the GPO through his/her in equity interest in Unified Physician Management Holdings, LP (UPM Holdings). UPM Holdings's and Unified Women's Healthcare, LP, the operator of the GPO, share a common general partner, Unified Physician Management, GP, LLC. The Interest is not freely transferable, remains subject to a risk of forfeiture as of the date of this filing and repurchase by UPM Holdings. Physician Covered Recipient No dispute reported 06/30/2026 800888479
PY2020 Unified Women's Healthcare, LP $0.00 $1.00 Physician holds an indirect ownership interest (Interest) in the GPO through his/her in equity interest in Unified Physician Management Holdings, LP (UPM Holdings). UPM Holdings's and Unified Women's Healthcare, LP, the operator of the GPO, share a common general partner, Unified Physician Management, GP, LLC. The Interest is not freely transferable, remains subject to a risk of forfeiture as of the date of this filing and repurchase by UPM Holdings. Physician Covered Recipient No dispute reported 06/30/2026 735549363